Thomas Danne, Germany

Children’s Hospital AUF DER BULT, Hannover Medical School Pediatrics

Prof. Dr. Thomas Danne is the Director of the Department of General Pediatrics Endocrinology/Diabetology & Clinical Research at the “Auf der Bult” Hospital for Children and Adolescents, Hannover Medical School, Germany, which is the largest pediatric diabetes center in Germany. Presently he is appointed as Chairman of the SWEET-project (www.sweet-project.eu) and work-package leader of the INNODIA-project (www.innodia.eu). He is the recipient of the “Lifetime Achievement Award” of the International Diabetes Federation 2017 and the “Helmut-Otto-Medal” and the “Hagedorn-Prize” of the German Diabetes Association. He is the Past-President of the International Society for Pediatric and Adolescent Diabetes (ISPAD), the German Diabetes Association (DDG) and the German Diabetes Aid (diabetesDE). He is a former Research Fellow of the Joslin Diabetes Center of Harvard Medical School in Boston. His research interests include basic and clinical research in pediatric diabetology with special emphasis on new insulins, insulin pumps, glucose sensors and the artificial pancreas.

Presenter of 5 Presentations

Conference Calendar

PARALLEL SESSION

Introduction

Date

Thu, 03.06.2021

Session Name

0200 - Live Q&A: Parallel Session 06: Thriving For Clinical Excellence (ID 24)

Lecture Time

17:15 - 17:17

Presenter

Thomas Danne, Germany

Authors

Thomas Danne, Germany

ORAL PRESENTATION SESSION

GLYCEMIC PROFILES AND TREATMENT PATTERNS: REAL-WORLD DATA FROM 13,109 PEOPLE IN EUROPE AND CANADA WITH DIABETES USING A TUBELESS INSULIN PUMP WITH CLOUD-BASED DATA MANAGEMENT

Date

Thu, 03.06.2021

Session Name

0280 - Oral Presentation 08 (ID 71)

Lecture Time

20:50 - 21:00

Presenter

Thomas Danne, Germany

Authors

Abstract

Abstract

Background and Aims

Real-world data has been recognized as an important tool to better understand the impact of diabetes technology on clinical outcomes of people with diabetes. This retrospective study analyzed data from a large cohort of patients with diabetes using a tubeless insulin pump (Omnipod^® Insulin Management System) with CGM or an integrated blood glucose (BG) meter and a data management system to characterize glycemic profiles, insulin use and treatment patterns.

Methods

Tubeless insulin pump data was generated between December 1, 2018 and November 30, 2019 and uploaded to the data management system from Europe and Canada. CGM, BG and insulin data from users with ≥3 months system use were analyzed.

Results

Data from 13,109 users from the United Kingdom (25.3%), Sweden (18.3%), the Netherlands (12.6%), Canada (29.2%) and other (14.6%) were included. Glycemic profiles (mean±SD) for the CGM cohort included mean glucose of 177±32mg/dL, and percentage time <70mg/dL of 5.6±4.3%, in target range (70 to 180mg/dL) of 52.6±14.6% and >180mg/dL of 41.8±15.9% (see Table for BG results). For the total population, mean total daily insulin was 40.6±17.6U/d which was delivered as 47% basal and 53% bolus. There was an average of 5.9±2.2 bolus deliveries per day and the average bolus amount was 4.2±2.5U.

Conclusions

This is the first study of real-world data on glycemic profiles and treatment patterns from a large cohort of people using a tubeless pump in Europe and Canada. It demonstrates glycemic levels comparable to published worldwide data using other means of intensive insulin regimens.

diasend table image-01.png